Abstract | PURPOSE OF REVIEW:
Myasthenia gravis is due to autoantibodies against components of the neuromuscular junction. Here, we analyzed the latest concepts of the physiopathological mechanisms and highlighted the recent findings about the immune-regulatory and etiological mechanisms. RECENT FINDINGS: SUMMARY: A better understanding of the pathogenic effects of the distinct myasthenia gravis autoantibodies may lead to new therapeutic interventions according to the myasthenia gravis subtype. Future investigations on the immunoregulatory mechanisms will also lead to therapeutic avenues able to restore the balance of the immune system and possibly lead to long-term remissions.
|
Authors | Rozen Le Panse, Sonia Berrih-Aknin |
Journal | Current opinion in neurology
(Curr Opin Neurol)
Vol. 26
Issue 5
Pg. 569-76
(Oct 2013)
ISSN: 1473-6551 [Electronic] England |
PMID | 23995274
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Autoantibodies
- Receptors, Cholinergic
- Receptor Protein-Tyrosine Kinases
|
Topics |
- Animals
- Autoantibodies
(immunology, therapeutic use)
- Humans
- Myasthenia Gravis
(diagnosis, etiology, immunology, therapy)
- Neuromuscular Junction
(immunology)
- Receptor Protein-Tyrosine Kinases
(immunology)
- Receptors, Cholinergic
(immunology)
- Risk Factors
|